NVS•benzinga•May 4, 2022 at 09:56 AM

New Novartis Data Demonstrate Kisqali Plus Fulvestrant Achieved a Median Overall Survival of More than Five-and-a-half Years in First-line Setting for Postmenopausal Women Living with HR+/HER2- aBC1

No summary available.

Read the full article from the original source for complete details and context.

Article published on May 4, 2022 by benzinga